| Literature DB >> 35942314 |
Yuan Yue1,2,3, Mei Shen4, Xiang Liu4, Qiong Hao4, Yutong Kang2, Yanlin Che2, Fang Li2, Shenglin Chen2, Shuai Xu2, Huaiqi Jing2, Zhen-Jun Li2, Xue-Zhang Zhou1.
Abstract
Focusing on resistance trends and transmission patterns of pathogenic microorganisms is a major priority for national surveillance programs. The use of whole-genome sequencing for antimicrobial susceptibility testing (WGS-AST) is a powerful alternative to traditional microbiology laboratory methods. Yersinia enterocolitica antimicrobial resistance (AMR) in the Ningxia Hui Autonomous Region has yet to be described thoroughly in current studies. We assessed and monitored the development of Y. enterocolitica AMR in the Ningxia Hui Autonomous Region during 2007-2019 based on WGS-AST. Resistance genotypes were predicted based on WGS. Antimicrobial resistance testing using classical microbiology determined resistance to 13 antimicrobial agents in 189 Y. enterocolitica isolates from Ningxia. The highest resistance level was 97.88% for cefazolin, followed by ampicillin (AMP) (44.97%), ciprofloxacin (CIP) (25.40%), streptomycin (STR) (11.11%), and tetracycline (TET) (10.58%). Isolates emerged as chloramphenicol (CHL) and trimethoprim/sulfamethoxazole (SXT) resistant. The primary plasmid types were IncFII(Y) and ColRNAI. The TET, STR, and SXT resistance were mediated by the tetA, aph(6)-Id, aph(3″)-Ib, and sul2 genes located on the IncQ1 plasmid. The resistant strains were predominantly biotype 4/O:3/ST429 and the hosts were pigs and patients. The number of multidrug-resistant (MDR) strains was of concern, at 27.51%. At present, the prediction of antimicrobial resistance based on WGS requires a combination of phenotypes. From 2007 to 2019, Y. enterocolitica isolates from the Ningxia Hui Autonomous Region showed a relatively high rate of resistance to cefazolin (CZO) and some resistance to AMP, CIP, STR, and TET. CIP, SXT, and TET showed a relatively clear trend of increasing resistance. Plasmids carrying multiple drug resistance genes are an important mechanism for the spread of antimicrobial resistance. Isolates with low pathogenicity were more likely to present an AMR phenotype than non-pathogenic isolates.Entities:
Keywords: Yersinia enterocolitica; antimicrobial resistance; multidrug-resistant; plasmid; whole-genome sequencing
Year: 2022 PMID: 35942314 PMCID: PMC9356307 DOI: 10.3389/fmicb.2022.936425
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 6.064
Biochemical tests used to biotype Y. enterocolitica strains (Bottone, 1997).
| Test | Biogroup reaction | |||||
| 1A | 1B | 2 | 3 | 4 | 5 | |
| Lipase activity | + | + | – | – | – | – |
| Salicin | + | – | – | – | – | – |
| Esculin hydrolysis | +/– | – | – | – | – | – |
| Xylose | + | + | + | + | – | v |
| Trehalose | + | + | + | + | + | – |
| Indole production | + | + | v | – | – | – |
| Ornithine decarboxylase | + | + | + | + | + | + (+) |
| Voges-Proskauer test | + | + | + | + | + | + (+) |
| Pyrazinamidase activity | + | – | – | – | – | – |
| Sorbose | + | + | + | + | + | – |
| Inositol | + | + | + | + | + | + |
| Nitrate reduction | + | + | + | + | + | – |
+, positive; −, negative; (+), delayed positive; v, variable.
Biotype and serotype of 189 Y. enterocolitica isolates.
| Biotype | O serotype | |||||||
| O:3 | O:5 | O:8 | O:9 | O:53 | O:1,2,5 | O:5,8,9 | O: unidentifiable | |
| 2 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 |
| 3 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 4 | 82 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| 5 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1A | 0 | 60 | 22 | 2 | 1 | 1 | 1 | 5 |
FIGURE 1The Minimum Spanning Trees (MST) of Y. enterocolitica isolates. STs were identified by the information on the allelic loci of aarF, dfp, galR, glnS, hemA, rfaE, and speA. (A) ST; (B) biotype; (C) serotype. The circle size was proportional to the number of isolates. Links between circles were represented according to the number of allelic differences between STs.
FIGURE 2The matrix of allele difference loci of strain. Both the X and Y axes indicated the sample name. Metadata for biotype, serotype, and host were presented.
Resistance rates of isolates from different sources.
| Antimicrobial agents | Animal ( | Food ( | Human ( | ||||||
| Pig ( | Sheep ( | Cattle ( | Rat ( | Chicken( | Total (n = 152) | ||||
| AMP | S (%) | 8.33 | 0 | 0 | 0 | 66.67 | 7.89 | 4.17 | 7.70 |
| I (%) | 40.83 | 83.33 | 50 | 40 | 33.33 | 46.05 | 62.5 | 38.46 | |
| R (%) | 50.83 | 16.67 | 50 | 60 | 0 | 46.05 | 33.33 | 53.85 | |
| SAM | S (%) | 65.83 | 88.89 | 66.67 | 40 | 100 | 68.42 | 83.33 | 53.85 |
| I (%) | 32.5 | 5.56 | 33.33 | 60 | 0 | 29.61 | 16.67 | 46.15 | |
| R (%) | 1.67 | 5.56 | 0 | 0 | 0 | 1.97 | 0 | 0 | |
| TET | S (%) | 85.83 | 100 | 100 | 100 | 100 | 88.82 | 91.67 | 53.85 |
| I (%) | 3.33 | 0 | 0 | 0 | 0 | 2.63 | 4.17 | 0 | |
| R (%) | 10.83 | 0 | 0 | 0 | 0 | 8.55 | 4.17 | 46.15 | |
| CZO | S (%) | 3.33 | 0 | 0 | 0 | 0 | 2.63 | 0 | 0 |
| I (%) | 0 | 0 | 0 | 0 | 33.33 | 0.66 | 0 | 7.70 | |
| R (%) | 96.67 | 100 | 100 | 100 | 66.67 | 96.71 | 100 | 92.30 | |
| CXM | S (%) | 99.17 | 94.44 | 100 | 100 | 100 | 98.68 | 100 | 76.92 |
| I (%) | 0.83 | 5.56 | 0 | 0 | 0 | 1.32 | 0 | 23.08 | |
| CAZ | S (%) | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 76.92 |
| I (%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 23.08 | |
| SXT | S (%) | 94.17 | 100 | 100 | 100 | 100 | 95.39 | 100 | 69.23 |
| R (%) | 5.83 | 0 | 0 | 0 | 0 | 4.61 | 0 | 30.77 | |
| POL | I (%) | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| CIP | S (%) | 54.17 | 100 | 83.33 | 100 | 100 | 63.16 | 75 | 38.46 |
| I (%) | 12.5 | 0 | 0 | 0 | 0 | 9.87 | 20.83 | 15.38 | |
| R (%) | 33.33 | 0 | 16.67 | 0 | 0 | 26.97 | 4.17 | 46.15 | |
| GEN | S (%) | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 92.30 |
| R (%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7.70 | |
| STR | S (%) | 88.33 | 100 | 100 | 100 | 100 | 90.79 | 91.67 | 61.54 |
| R (%) | 11.67 | 0 | 0 | 0 | 0 | 9.21 | 8.33 | 38.46 | |
| CHL | S (%) | 100 | 100 | 100 | 100 | 100 | 100 | 91.67 | 61.54 |
| R (%) | 0 | 0 | 0 | 0 | 0 | 0 | 8.33 | 38.46 | |
| IPM | S (%) | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
AMP, ampicillin; SAM, ampicillin/sulbactam, TET, tetracycline; CZO, cefazolin; CXM, cefuroxime; CAZ, ceftazidime; SXT, trimethoprim/sulfamethoxazole; POL, polymyxin; CIP, ciprofloxacin; GEN, gentamicin; STR, streptomycin; CHL, chloramphenicol; IPM, imipenem; I, intermediate resistant; S, susceptibility. Different superscript lowercase letters indicate significant differences (p < 0.05). The same superscript lowercase letters indicate no statistical difference. No superscript letters indicate not applicable.
Resistance rates of pathogenic and non-pathogenic isolates.
| Antimicrobial agents | Pathogenic (n = 96) | Non-pathogenic ( | |||||
| 4/O:3 ( | 3/O:3 ( | 5/O:3 ( | 2/O:9 ( | Total ( | |||
| AMP | S | 9 | 0 | 0 | 0 | 9 | 3 |
| I | 31 | 2 | 7 | 2 | 42 | 45 | |
| R | 42 | 2 | 0 | 1 | 45 | 39 | |
| SAM | S | 55 | 3 | 7 | 2 | 67 | 61 |
| I | 26 | 1 | 0 | 1 | 28 | 25 | |
| R | 1 | 0 | 0 | 0 | 1 | 1 | |
| TET | S | 64 | 4 | 7 | 3 | 78 | 81 |
| I | 1 | 0 | 0 | 0 | 1 | 3 | |
| R | 17 | 0 | 0 | 0 | 17 | 3 | |
| CZO | S | 3 | 1 | 0 | 0 | 4 | 0 |
| I | 0 | 0 | 0 | 0 | 0 | 1 | |
| R | 79 | 3 | 7 | 3 | 92 | 86 | |
| CXM | S | 79 | 4 | 7 | 3 | 93 | 86 |
| I | 3 | 0 | 0 | 0 | 3 | 1 | |
| CAZ | S | 79 | 4 | 7 | 3 | 93 | 87 |
| I | 3 | 0 | 0 | 0 | 3 | 0 | |
| SXT | S | 71 | 4 | 7 | 3 | 85 | 87 |
| R | 11 | 0 | 0 | 0 | 11 | 0 | |
| CIP | S | 30 | 1 | 7 | 3 | 41 | 74 |
| I | 14 | 0 | 0 | 0 | 14 | 7 | |
| R | 38 | 3 | 0 | 0 | 41 | 6 | |
| GEN | S | 81 | 4 | 7 | 3 | 95 | 87 |
| R | 1 | 0 | 0 | 0 | 1 | 0 | |
| STR | S | 67 | 3 | 7 | 3 | 80 | 82 |
| R | 15 | 1 | 0 | 0 | 16 | 5 | |
| CHL | S | 78 | 4 | 7 | 3 | 92 | 85 |
| R | 4 | 0 | 0 | 0 | 4 | 2 | |
| POL | I | 82 | 4 | 7 | 3 | 96 | 87 |
| IPM | S | 82 | 4 | 7 | 3 | 96 | 87 |
AMP, ampicillin; SAM, ampicillin/sulbactam, TET, tetracycline; CZO, cefazolin; CXM, cefuroxime; CAZ, ceftazidime; SXT, trimethoprim/sulfamethoxazole; POL, polymyxin; CIP, ciprofloxacin; GEN, gentamicin; STR, streptomycin; CHL, chloramphenicol; IPM, imipenem; R, resistant; I, intermediate resistant; S, susceptibility. Different superscript lowercase letters indicate significant differences (p < 0.05). The same superscript lowercase letters indicate no statistical difference. No superscript letters indicate not applicable.
FIGURE 3Distribution of antimicrobial resistance (AMR) genes and plasmids in 189 Y. enterocolitica strains. Metadata for biotype, host, serotype, STs, CTs, and resistance mechanism were presented. The 20 HC100 in different colors indicated 20 genetic clusters with a threshold of sharing 100 cgMLST alleles, linked by single-stranded clustering criteria. Gray CTs indicated the other 42 HC100.
The genotypic and phenotypic correlations of the AMR genes.
| Category | AMR gene | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | Note |
| β-lactams | 49.43 | 69.23 | 95.60 | 9.18% | AMP | |
| 0 | 1.06 | 0 | 100 | IPM | ||
| Cephalosporins | 98.91 | 0 | 96.79 | 0 | CZO | |
| 0 | 1.06% | 0 | 100 | CAZ | ||
| 0 | 1.06% | 0 | 100 | CXM | ||
|
| 1.64 | 100 | 100 | 3.23 | CZO | |
| 0 | 100 | 0 | 3.23 | CAZ | ||
| 0 | 100 | 0 | 3.23 | CXM | ||
|
| 0.55 | 100 | 100 | 3.19 | CZO | |
| 0 | 99.47 | 0 | 100 | CAZ | ||
| 0 | 99.47 | 0 | 100 | CXM | ||
| Tetracyclines | 76.92 | 97.55 | 83.33 | 96.36 | ||
| 15.38 | 100 | 100 | 88.11 | |||
| Trimethoprim/sulfamethoxazole | 9.09 | 97.75 | 20 | 94.57 | ||
| 100 | 84.83 | 28.95 | 100 | |||
| 9.09 | 100 | 100 | 94.68 | |||
| Fluoroquinolones | QnrD1 | 0 | 99.15 | 0 | 62.23 | |
| QnrS1 | 0 | 99.15 | 0 | 62.23 | ||
| Aminoglycosides | 100 | 100 | 100 | 100 | GEN | |
| 4.76 | 100 | 100 | 89.36 | STR | ||
| 100 | 89.89 | 5 | 100 | GEN | ||
| 90.48 | 100 | 100 | 98.82 | STR | ||
| 0 | 99.47 | 0 | 99.47 | GEN | ||
| 4.76 | 100 | 100 | 89.36 | STR | ||
| 100 | 89.89 | 5 | 100 | GEN | ||
| 90.48 | 100 | 100 | 98.82 | STR | ||
| 100 | 100 | 100 | 100 | GEN | ||
| 4.76 | 100 | 100 | 89.36 | STR | ||
| 0 | 98.40 | 0 | 99.46 | GEN | ||
| 14.29 | 100 | 100 | 90.32 | STR | ||
| Chloramphenicols | 14.29 | 100 | 100 | 96.81 | ||
| 14.29 | 100 | 100 | 96.81 | |||
| 85.71 | 99.45 | 85.71 | 99.45 |
AMP, ampicillin; CZO, cefazolin; CXM, cefuroxime; CAZ, ceftazidime; GEN, gentamicin; STR, streptomycin; IPM, imipenem; PPV, Positive predictive Value; NPV, negative predictive value.
FIGURE 4Resistance rates of pig-derived strains from 2007 to 2019. AMP, ampicillin; TET, tetracycline; SXT, trimethoprim/sulfamethoxazole; CIP, ciprofloxacin; STR, streptomycin.